Published in PLoS Med on January 01, 2007
Public health interventions and epidemic intensity during the 1918 influenza pandemic. Proc Natl Acad Sci U S A (2007) 5.90
Preliminary findings of a randomized trial of non-pharmaceutical interventions to prevent influenza transmission in households. PLoS One (2008) 2.04
Evidence-based tool for triggering school closures during influenza outbreaks, Japan. Emerg Infect Dis (2009) 2.02
Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med (2009) 1.99
Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1). BMC Med (2009) 1.92
A small community model for the transmission of infectious diseases: comparison of school closure as an intervention in individual-based models of an influenza pandemic. PLoS One (2008) 1.84
Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1. Biosecur Bioterror (2011) 1.75
Population-wide emergence of antiviral resistance during pandemic influenza. PLoS One (2008) 1.71
What is the best control strategy for multiple infectious disease outbreaks? Proc Biol Sci (2007) 1.68
Virtual epidemic in a virtual city: simulating the spread of influenza in a US metropolitan area. Transl Res (2008) 1.68
Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Comput Biol (2007) 1.64
Dynamics of influenza virus infection and pathology. J Virol (2010) 1.62
Simulation suggests that rapid activation of social distancing can arrest epidemic development due to a novel strain of influenza. BMC Public Health (2009) 1.58
Influenza--insights from mathematical modelling. Dtsch Arztebl Int (2009) 1.51
Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proc Biol Sci (2007) 1.49
Effective, robust design of community mitigation for pandemic influenza: a systematic examination of proposed US guidance. PLoS One (2008) 1.47
Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J Virol (2010) 1.31
Antiviral treatment for the control of pandemic influenza: some logistical constraints. J R Soc Interface (2008) 1.31
Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs. PLoS One (2008) 1.26
Defining Hsp70 Subnetworks in Dengue Virus Replication Reveals Key Vulnerability in Flavivirus Infection. Cell (2015) 1.20
Antiviral resistance during pandemic influenza: implications for stockpiling and drug use. BMC Infect Dis (2009) 1.17
Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg Infect Dis (2008) 1.16
Meeting report: risk assessment of tamiflu use under pandemic conditions. Environ Health Perspect (2008) 1.15
Optimal control of epidemics with limited resources. J Math Biol (2010) 1.13
The effect of population structure on the emergence of drug resistance during influenza pandemics. J R Soc Interface (2007) 1.12
Influenza antiviral resistance testing in new york and wisconsin, 2006 to 2008: methodology and surveillance data. J Clin Microbiol (2009) 1.10
Evaluation of targeted influenza vaccination strategies via population modeling. PLoS One (2010) 1.10
Evolution in health and medicine Sackler colloquium: a public choice framework for controlling transmissible and evolving diseases. Proc Natl Acad Sci U S A (2009) 1.10
Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine (2009) 1.09
Theoretical basis to measure the impact of short-lasting control of an infectious disease on the epidemic peak. Theor Biol Med Model (2011) 1.07
Does the effectiveness of control measures depend on the influenza pandemic profile? PLoS One (2008) 1.05
Antiviral resistance and the control of pandemic influenza: the roles of stochasticity, evolution and model details. J Theor Biol (2008) 1.03
Mitigation strategies for pandemic influenza A: balancing conflicting policy objectives. PLoS Comput Biol (2011) 1.03
Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines. J R Soc Interface (2009) 1.01
Optimizing tactics for use of the U.S. antiviral strategic national stockpile for pandemic influenza. PLoS One (2011) 1.00
When does overuse of antibiotics become a tragedy of the commons? PLoS One (2012) 0.99
Structural vaccinology: structure-based design of influenza A virus hemagglutinin subtype-specific subunit vaccines. Protein Cell (2012) 0.98
Post-exposure prophylaxis during pandemic outbreaks. BMC Med (2009) 0.97
Antiviral prophylaxis during pandemic influenza may increase drug resistance. BMC Infect Dis (2009) 0.96
Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model. J Virol (2010) 0.95
Diagnosis and antiviral intervention strategies for mitigating an influenza epidemic. PLoS One (2011) 0.94
A model-based assessment of oseltamivir prophylaxis strategies to prevent influenza in nursing homes. Emerg Infect Dis (2009) 0.93
The use of mathematical models to inform influenza pandemic preparedness and response. Exp Biol Med (Maywood) (2011) 0.91
Decision making with regard to antiviral intervention during an influenza pandemic. Med Decis Making (2010) 0.90
Targeting imperfect vaccines against drug-resistance determinants: a strategy for countering the rise of drug resistance. PLoS One (2013) 0.90
Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. J Virol (2014) 0.90
Evolutionary epidemiology of drug-resistance in space. PLoS Comput Biol (2009) 0.89
Optimizing tactics for use of the U.S. Antiviral Strategic National Stockpile for Pandemic (H1N1) Influenza, 2009. PLoS Curr (2009) 0.88
Antiviral usage for H1N1 treatment: pros, cons and an argument for broader prescribing guidelines in the United States. PLoS Curr (2009) 0.87
Optimal antiviral treatment strategies and the effects of resistance. Proc Biol Sci (2010) 0.87
The timing and targeting of treatment in influenza pandemics influences the emergence of resistance in structured populations. PLoS Comput Biol (2013) 0.86
In Vitro Susceptibility of Canine Influenza A (H3N8) Virus to Nitazoxanide and Tizoxanide. Vet Med Int (2010) 0.86
Mathematical assessment of Canada's pandemic influenza preparedness plan. Can J Infect Dis Med Microbiol (2008) 0.85
Intervention strategies for an influenza pandemic taking into account secondary bacterial infections. Epidemics (2009) 0.85
Access, excess, and ethics--towards a sustainable distribution model for antibiotics. Ups J Med Sci (2014) 0.85
Antiviral drugs for treatment of patients infected with pandemic (H1N1) 2009 virus. Emerg Infect Dis (2009) 0.85
Modeling the effects of vaccination and treatment on pandemic influenza. AAPS J (2011) 0.85
A mathematical framework for estimating pathogen transmission fitness and inoculum size using data from a competitive mixtures animal model. PLoS Comput Biol (2011) 0.84
Predispensing of antivirals to high-risk individuals in an influenza pandemic. PLoS Curr (2009) 0.84
Strategies for the use of oseltamivir and zanamivir during pandemic outbreaks. Can J Infect Dis Med Microbiol (2010) 0.83
Pre-dispensing of antivirals to high-risk individuals in an influenza pandemic. Influenza Other Respir Viruses (2010) 0.83
Antibiotic use as a tragedy of the commons: a cross-sectional survey. Comput Math Methods Med (2014) 0.82
Influenza virus assays based on virus-inducible reporter cell lines. Influenza Other Respir Viruses (2009) 0.81
The cost effectiveness of pandemic influenza interventions: a pandemic severity based analysis. PLoS One (2013) 0.81
Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection. Antimicrob Agents Chemother (2008) 0.80
Paradox of vaccination: is vaccination really effective against avian flu epidemics? PLoS One (2009) 0.79
Can treatment increase the epidemic size? J Math Biol (2015) 0.79
Influenza pandemic waves under various mitigation strategies with 2009 H1N1 as a case study. PLoS One (2010) 0.79
A model-guided analysis and perspective on the evolution and epidemiology of antibiotic resistance and its future. Curr Opin Microbiol (2014) 0.78
Timing of antimicrobial use influences the evolution of antimicrobial resistance during disease epidemics. Evol Med Public Health (2014) 0.77
Design of non-pharmaceutical intervention strategies for pandemic influenza outbreaks. BMC Public Health (2014) 0.77
Optimizing treatment regimes to hinder antiviral resistance in influenza across time scales. PLoS One (2013) 0.77
Modelers' perception of mathematical modeling in epidemiology: a web-based survey. PLoS One (2011) 0.76
Effects of influenza antivirals on individual and population immunity over many epidemic waves. Epidemiol Infect (2012) 0.76
Temporally Varying Relative Risks for Infectious Diseases: Implications for Infectious Disease Control. Epidemiology (2017) 0.75
Population dynamics of epidemic and endemic states of drug-resistance emergence in infectious diseases. PeerJ (2017) 0.75
Bygiene: The New Paradigm of Bidirectional Hygiene. Yale J Biol Med (2015) 0.75
Predictive and Reactive Distribution of Vaccines and Antivirals during Cross-Regional Pandemic Outbreaks. Influenza Res Treat (2011) 0.75
Dynamical crises, multistability and the influence of the duration of immunity in a seasonally-forced model of disease transmission. Theor Biol Med Model (2014) 0.75
How to minimize the attack rate during multiple influenza outbreaks in a heterogeneous population. PLoS One (2012) 0.75
Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic. Western Pac Surveill Response J (2012) 0.75
Optimality of a time-dependent treatment profile during an epidemic. J Biol Dyn (2013) 0.75
Two resource distribution strategies for dynamic mitigation of influenza pandemics. J Multidiscip Healthc (2010) 0.75
Mass oseltamivir prophylaxis halts pandemic influenza A H1N1 2009 outbreak in a secondary school in Ashanti Region, Ghana. Ghana Med J (2012) 0.75
Data-driven interdisciplinary mathematical modelling quantitatively unveils competition dynamics of co-circulating influenza strains. J Transl Med (2017) 0.75
Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies. Infect Drug Resist (2017) 0.75
Host population structure impedes reversion to drug sensitivity after discontinuation of treatment. PLoS Comput Biol (2017) 0.75
Strategies for mitigating an influenza pandemic. Nature (2006) 25.20
Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A (2006) 17.88
Transmissibility of 1918 pandemic influenza. Nature (2004) 16.14
Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med (2005) 15.53
Containing pandemic influenza with antiviral agents. Am J Epidemiol (2004) 12.82
Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet (2004) 8.62
Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA (2006) 8.06
Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. Am J Epidemiol (2006) 7.39
Avian flu: isolation of drug-resistant H5N1 virus. Nature (2005) 6.66
The biological cost of antibiotic resistance. Curr Opin Microbiol (1999) 6.08
Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis (2004) 4.82
Oseltamivir resistance--disabling our influenza defenses. N Engl J Med (2005) 4.41
Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother (2006) 4.02
The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Natl Acad Sci U S A (2000) 3.56
Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother (2005) 3.53
Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A (1997) 3.48
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother (2005) 3.04
Design and Evaluation of Prophylactic Interventions Using Infectious Disease Incidence Data from Close Contact Groups. J R Stat Soc Ser C Appl Stat (2006) 2.97
Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol (1996) 2.95
Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med (2004) 2.83
The rise and fall of antimicrobial resistance. Trends Microbiol (2001) 2.79
Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis (2006) 2.76
Emergence of drug-resistant influenza virus: population dynamical considerations. Science (2006) 2.46
Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis (2006) 2.29
The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis (2003) 2.17
Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res (2006) 2.11
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A (2006) 2.00
Biologic potential of amantadine-resistant influenza A virus in an avian model. J Infect Dis (1989) 2.00
A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J Antimicrob Chemother (2003) 1.92
Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis (1998) 1.85
Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr (2006) 1.53
International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr (2001) 1.46
Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir Ther (2005) 1.33
Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations. Am J Epidemiol (2005) 1.31
International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr (2001) 1.19
Isoniazid resistance and the future of drug-resistant tuberculosis. Microb Drug Resist (2004) 1.16
Oseltamivir-resistant influenza? Lancet (2004) 0.97
Transmission dynamics and control of severe acute respiratory syndrome. Science (2003) 14.70
Seasonality of antibiotic-resistant streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic-restriction policy? J Infect Dis (2008) 7.76
Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology (2010) 5.12
Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med (2007) 4.51
Biological and biomedical implications of the co-evolution of pathogens and their hosts. Nat Genet (2002) 4.42
Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet (2010) 3.32
Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med (2009) 2.95
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med (2010) 2.86
Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med (2004) 2.83
Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet (2013) 2.80
Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother (2006) 2.69
Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med (2012) 2.54
Excellent clinical outcomes and high retention in care among adults in a community-based HIV treatment program in rural Rwanda. J Acquir Immune Defic Syndr (2012) 2.48
Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med (2008) 2.33
Tuberculosis and poverty: why are the poor at greater risk in India? PLoS One (2012) 2.31
Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med (2006) 2.28
Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci Transl Med (2013) 2.28
Interpreting expression data with metabolic flux models: predicting Mycobacterium tuberculosis mycolic acid production. PLoS Comput Biol (2009) 2.28
Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study. Lancet (2008) 2.27
Functional relationship between bacterial cell density and the efficacy of antibiotics. J Antimicrob Chemother (2009) 2.24
Towards universal health coverage: an evaluation of Rwanda Mutuelles in its first eight years. PLoS One (2012) 2.22
The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis (2003) 2.17
Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis (2010) 2.14
Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. Int J Epidemiol (2011) 2.07
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A (2006) 2.00
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2006) 1.98
Dealing with the evolutionary downside of CRISPR immunity: bacteria and beneficial plasmids. PLoS Genet (2013) 1.97
Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother (2004) 1.93
Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet (2013) 1.93
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med (2011) 1.87
Genomewide pattern of synonymous nucleotide substitution in two complete genomes of Mycobacterium tuberculosis. Emerg Infect Dis (2002) 1.81
Reassessment of the 2010-2011 Haiti cholera outbreak and rainfall-driven multiseason projections. Proc Natl Acad Sci U S A (2012) 1.72
Modeling the role of bacteriophage in the control of cholera outbreaks. Proc Natl Acad Sci U S A (2006) 1.68
Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother (2004) 1.67
Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Sci Transl Med (2012) 1.65
Comprehensive and integrated district health systems strengthening: the Rwanda Population Health Implementation and Training (PHIT) Partnership. BMC Health Serv Res (2013) 1.64
Identifying multidrug resistant tuberculosis transmission hotspots using routinely collected data. Tuberculosis (Edinb) (2012) 1.63
Expanding tuberculosis case detection by screening household contacts. Public Health Rep (2005) 1.58
The evolution of mutator genes in bacterial populations: the roles of environmental change and timing. Genetics (2003) 1.58
A comparative lipidomics platform for chemotaxonomic analysis of Mycobacterium tuberculosis. Chem Biol (2011) 1.56
Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission. J R Soc Interface (2007) 1.54
The anticipated severity of a "1918-like" influenza pandemic in contemporary populations: the contribution of antibacterial interventions. PLoS One (2012) 1.47
Grazing protozoa and the evolution of the Escherichia coli O157:H7 Shiga toxin-encoding prophage. Proc Biol Sci (2007) 1.44
The ecology of nasal colonization of Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus: the role of competition and interactions with host's immune response. BMC Microbiol (2010) 1.44
Mixed-strain Mycobacterium tuberculosis infections among patients dying in a hospital in KwaZulu-Natal, South Africa. J Clin Microbiol (2010) 1.42
No coexistence for free: neutral null models for multistrain pathogens. Epidemics (2008) 1.37
Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol (2002) 1.36
Use of cumulative incidence of novel influenza A/H1N1 in foreign travelers to estimate lower bounds on cumulative incidence in Mexico. PLoS One (2009) 1.33
Isolation of tumor cells using size and deformation. J Chromatogr A (2009) 1.31
What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae? J R Soc Interface (2009) 1.30
The application of ultraviolet germicidal irradiation to control transmission of airborne disease: bioterrorism countermeasure. Public Health Rep (2003) 1.29
Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis (2012) 1.28
The impact of new tuberculosis diagnostics on transmission: why context matters. Bull World Health Organ (2012) 1.27
Epidemiologic inference from the distribution of tuberculosis cases in households in Lima, Peru. J Infect Dis (2011) 1.25
Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus. PLoS Genet (2013) 1.23
Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med (2010) 1.22
Use of whole genome sequencing to determine the microevolution of Mycobacterium tuberculosis during an outbreak. PLoS One (2013) 1.19
Incident tuberculosis among recent US immigrants and exogenous reinfection. Emerg Infect Dis (2005) 1.13
Antibiotics in agriculture: when is it time to close the barn door? Proc Natl Acad Sci U S A (2002) 1.13
Aminoglycoside cross-resistance in Mycobacterium tuberculosis due to mutations in the 5' untranslated region of whiB7. Antimicrob Agents Chemother (2013) 1.09
Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PLoS One (2011) 1.09
Within-host evolution for the invasiveness of commensal bacteria: an experimental study of bacteremias resulting from Haemophilus influenzae nasal carriage. J Infect Dis (2007) 1.09
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. PLoS One (2011) 1.08
Multiple introductions of multidrug-resistant tuberculosis into households, Lima, Peru. Emerg Infect Dis (2011) 1.07
Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum. PLoS Pathog (2012) 1.06
How the dynamics and structure of sexual contact networks shape pathogen phylogenies. PLoS Comput Biol (2013) 1.05
High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova. Eur Respir J (2014) 1.04
Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J (2012) 1.04
Models to understand the population-level impact of mixed strain M. tuberculosis infections. J Theor Biol (2011) 1.04
Epidemiology, hypermutation, within-host evolution and the virulence of Neisseria meningitidis. Proc Biol Sci (2003) 1.04
Clinical research and development of tuberculosis diagnostics: moving from silos to synergy. J Infect Dis (2012) 1.03
Potential of rapid diagnosis for controlling drug-susceptible and drug-resistant tuberculosis in communities where Mycobacterium tuberculosis infections are highly prevalent. J Clin Microbiol (2009) 1.02
Siderocalin inhibits the intracellular replication of Mycobacterium tuberculosis in macrophages. FEMS Immunol Med Microbiol (2009) 1.02
The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa: results from three tuberculosis-HIV transmission models. AIDS (2014) 1.01
An experimental study of the population and evolutionary dynamics of Vibrio cholerae O1 and the bacteriophage JSF4. Proc Biol Sci (2010) 1.00
Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines. Proc Natl Acad Sci U S A (2008) 1.00
The population dynamics of bacteria in physically structured habitats and the adaptive virtue of random motility. Proc Natl Acad Sci U S A (2011) 0.99
Exploring the role of the immune response in preventing antibiotic resistance. J Theor Biol (2008) 0.99
Latent coinfection and the maintenance of strain diversity. Bull Math Biol (2008) 0.99
Tuberculosis among participants in an academic global health medical exchange program. J Gen Intern Med (2011) 0.98
Personal digital assistants to collect tuberculosis bacteriology data in Peru reduce delays, errors, and workload, and are acceptable to users: cluster randomized controlled trial. Int J Infect Dis (2008) 0.98
Adjustment for missing data in complex surveys using doubly robust estimation: application to commercial sexual contact among Indian men. Epidemiology (2010) 0.98
Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFα drugs. Curr Opin Pulm Med (2012) 0.97
The evolution of contact-dependent inhibition in non-growing populations of Escherichia coli. Proc Biol Sci (2008) 0.97
Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study. PLoS One (2008) 0.96
Controversies and unresolved issues in tuberculosis prevention and control: a low-burden-country perspective. J Infect Dis (2012) 0.95
Normal mutation rate variants arise in a Mutator (Mut S) Escherichia coli population. PLoS One (2013) 0.94
The effect of HIV-related immunosuppression on the risk of tuberculosis transmission to household contacts. Clin Infect Dis (2013) 0.94
Insertions, deletions, and single-nucleotide polymorphisms at rare restriction enzyme sites enhance discriminatory power of polymorphic amplified typing sequences, a novel strain typing system for Escherichia coli O157:H7. J Clin Microbiol (2004) 0.94
Mathematical models of the epidemiology and control of drug-resistant TB. Expert Rev Respir Med (2009) 0.94
Multidrug resistance among new tuberculosis cases: detecting local variation through lot quality-assurance sampling. Epidemiology (2012) 0.93
The pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulations. PLoS Pathog (2013) 0.93